From Yahoo Finance: 2025-05-26 09:47:00

Sound Shore Management, an investment firm, saw its Investor and Institutional Class funds decline in the first quarter of 2025. Their 35-year annualized returns were ahead of the Russell Value but trailed the S&P 500. Teva Pharmaceutical Industries Limited stock had a one-month return of 14.06% and closed at $16.96 per share on May 23, 2025.

In its Q1 2025 investor letter, Sound Shore Management discussed Teva Pharmaceutical Industries Limited’s impact on its portfolio. Teva develops generic and specialty drugs, focusing on neurological and respiratory diseases. The company’s recent leadership changes have led to improved margins and positive clinical trial results. Teva stock remains attractively priced, prompting Sound Shore Management to increase its position.

Teva Pharmaceutical Industries Limited was not among the 30 most popular stocks among hedge funds in Q1 2025, with 64 hedge fund portfolios holding the stock. Teva reported revenue of $3.9 billion in the first quarter, showing a 2% increase in U.S. dollars. While Teva has investment potential, hedge funds believe AI stocks offer greater returns in a shorter timeframe. If you’re interested in undervalued AI stocks with high growth potential, check out their report.



Read more at Yahoo Finance: Regulatory Shake-Up Led to the Sell Off in Teva Pharmaceutical Industries Limited (TEVA)